Introduction
============

The incidence of pancreatic neuroendocrine tumors (PNETs), which were previously considered rare heterogeneous tumors, has almost doubled to 10% over the past two decades.[@b1-ott-11-975],[@b2-ott-11-975] PNETs account for \~1%--2% of all pancreatic neoplasms and 7.0% of all neuroendocrine tumors.[@b3-ott-11-975] Surgery remains the only potentially curative treatment for PNETs, but its indication is often limited by the fact that most patients with PNETs present with metastatic disease at diagnosis. Several studies have demonstrated that liver metastases are found in \>50% of patients affected by PNETs (80% of cases are bilobar).[@b4-ott-11-975] However, the clinical course of the disease is usually characterized by a relatively indolent history and it has a 5-year survival rate exceeding 60%.[@b5-ott-11-975] This feature is due to the tendency to promote aggressive surgery, even in the presence of liver metastases. This aggressive surgical approach seems justified whenever radical resection may be achieved on both the primary tumor and the liver metastases.[@b6-ott-11-975]--[@b8-ott-11-975] However, in patients who are unsuitable for radical resection due to local vascular infiltration or liver metastases that extend to both liver lobes, or due to extrahepatic metastases, the indication for surgery remains highly controversial.[@b9-ott-11-975],[@b10-ott-11-975]

Cytoreductive surgery, also termed debulking, refers to the greatest possible reduction of the tumor mass in the context of the persistence of metastases and is generally carried out when it is possible to remove 70%--90% of the disease.[@b11-ott-11-975] However, the indication for primary PNET removal in the presence of unresectable liver metastases is controversial: studies have shown that this practice could provide relief from hormonal and local tumor-related symptoms and increase disease control,[@b12-ott-11-975]--[@b15-ott-11-975] but data on the possible amelioration of survival rates are scanty and affected by selection bias.

We therefore designed a systematic review to compare the effects of the primary tumor resection with those of nonsurgical regimens in patients with PNETs and unresectable liver metastases.

Methods
=======

Search strategy
---------------

An in-depth literature search was performed with the following search terms: (neuroendocrine tumor OR endocrine tumor OR neuroendocrine tumor OR endocrine tumor OR islet cell carcinoma OR beta-cell tumor OR pancreatic endocrine tumor OR pancreatic endocrine tumor OR islet cell tumor) AND (operative surgical procedure OR operative surgical OR operative procedure OR pancreatectomy OR pancreatectomies OR pancreaticoduodenectomy OR pancreatoduodenectomies OR duodenopancreatectomy OR duodenopancreatectomies OR primary resection OR splenopancreatectomy OR primary tumor resection OR primary tumor resection) AND (metastatic OR metastasis OR secondary OR advanced OR residual neoplasm OR residual cancer OR residual tumor) AND (liver OR hepatic). We searched the computerized databases PubMed and Cochrane to identify eligible studies in English-language journals before June 2017.

The references of each of the included studies were also screened for any additionally relevant articles. The titles of all identified articles were screened to ascertain their relevance. Abstracts and/or full texts of selected potentially relevant papers were further evaluated.

Selection criteria
------------------

Only studies that reported the survival of patients with PNETs and unresectable liver metastases (regardless of the presence or absence of extrahepatic disease, tumor grade, or functional status) were considered. Studies were included regardless of study type, publication status, or sample size. We intended to analyze randomized controlled trials (RCTs), quasi-RCTs, and non-RCTs, but given the likely paucity of high-quality research on the topic, prospective or retrospective cohort studies were also considered. Case--control studies, case series, case reports, and other observational studies were excluded.

Studies that reported survival outcomes following a direct comparison between patients who underwent primary tumor resection and those who did not undergo resection were included. In both the surgical and nonsurgical groups, other medical (somatostatin analogs, chemotherapy, peptide receptor radiotherapy) or ablative (transarterial chemoembolization, radiofrequency ablation, cryoablation) treatments were permitted. In the case of duplicate publications, the most recent or most complete data were included.

Two independent reviewers (BZ and YD) carried out the study identification, selection, and data extraction. If there was no consensus, the principal investigator (SZ) made the final decision on study eligibility and data extraction.

Data extraction
---------------

From the studies that met the eligibility criteria, the following data were collected: 1) study: publication year, study design, and study location; 2) cases: number of included patients, age, gender, site of primary tumor, and function; 3) intervention: type of surgery in the surgical group ± additional treatments, postoperative complications, and mortality; type of nonsurgical interventions; 4) median follow-up; and 5) survival outcomes were extracted as hazard ratios (HRs) from univariate or multivariate Cox regression models or as the median overall survival time (MOS) or overall survival rate at specific time points, as applicable.

Statistical analysis
--------------------

Data management and analyses were performed with RevMan 5.3 via the following methods: by calculating the relative risk with 95% confidence interval for dichotomous variables and by calculating the mean difference for continuous variables. Studies that reported HRs for survival in the surgical vs nonsurgical groups were pooled with a fixed-effect meta-analysis model, and a random-effect meta-analysis was conducted to investigate the liver tumor burden and tumor grade among patients who received surgery or nonsurgical therapy.

Additionally, heterogeneity measured as *I*^2^ was used to assess the percentage of total variation from all of the studies to define heterogeneity. A high value of *I*^2^ indicates heterogeneity. Publication bias was evaluated via Egger's test in this statistical analysis.

Results
=======

Literature search
-----------------

The flowchart of the included studies is shown in [Figure 1](#f1-ott-11-975){ref-type="fig"}. Overall, 1,689 records were identified through the PubMed and Cochrane search. According to the predefined inclusion and exclusion criteria, 10 studies published from 2001 to 2017 were included in the meta-analysis. Unfortunately, none of the identified studies were RCTs or quasi-RCTs. All were retrospective cohort studies based on either single-center cohort (n=8) or national database cohort (n=2).

Study characteristics
---------------------

Descriptive characteristics of the included studies are listed in [Table 1](#t1-ott-11-975){ref-type="table"}.[@b9-ott-11-975],[@b16-ott-11-975]--[@b24-ott-11-975] These studies included 1,226 patients who underwent palliative surgical resection of their primary tumor and 1,623 patients who did not receive surgery. Five studies were conducted in Italy:[@b16-ott-11-975]--[@b20-ott-11-975] three in the United States,[@b9-ott-11-975],[@b21-ott-11-975],[@b23-ott-11-975] one in China,[@b22-ott-11-975] and one in Germany.[@b24-ott-11-975] The number of included patients ranged from 43 to 2,158, and the median age ranged from 49 to 60 years. However, the median age was not explicitly stated in three publications.[@b16-ott-11-975],[@b18-ott-11-975],[@b24-ott-11-975] When the gender distributions were reported, most studies had similar numbers of males and females (males ranged from 47 to 66.9%).

In two studies, PNETs were mixed with neuroendocrine tumors (NETs) from sites other than the pancreas, including the ileum, lung, stomach, esophagus, rectum, and unknown primary.[@b17-ott-11-975],[@b22-ott-11-975] Furthermore, four studies included a certain proportion of patients without liver metastasis.[@b9-ott-11-975],[@b21-ott-11-975],[@b23-ott-11-975],[@b24-ott-11-975] Three of the 10 studies included only the nonfunctional PNET,[@b9-ott-11-975],[@b19-ott-11-975],[@b23-ott-11-975] and the study by Citterio et al[@b17-ott-11-975] reported the effect of primary tumor resection in patients with functional NET with liver metastases. The postoperative mortality was 0, while the rate of postoperative abdominal complications, including pancreatic fistula, abdominal fluid collections, and bleeding, ranged from 15.9 to 42.1% ([Table 2](#t2-ott-11-975){ref-type="table"}).

Tumor characteristics in the surgical and nonsurgical groups
------------------------------------------------------------

As several studies suggested that patients who underwent an aggressive surgical approach had a higher possibility of advanced disease or a heavy burden of liver metastasis, we further compared these differences between the groups ([Table 3](#t3-ott-11-975){ref-type="table"}). The meta-analysis demonstrated that there were no significant differences in liver tumor burden (odds ratio \[OR\] =1.51, 95% CI: 0.59--3.89, *P*=0.39) ([Figure 2](#f2-ott-11-975){ref-type="fig"}) or tumor grade (OR =2.88, 95% CI: 0.92--9.04, *P*=0.07) ([Figure 3](#f3-ott-11-975){ref-type="fig"}) among patients who received surgery or nonsurgical therapy; however, patients who underwent an aggressive surgical approach appeared to have a higher tumor grade. No significant heterogeneity was observed in the models for liver tumor burden (*P*=0.09, *I*^2^=54%), but there was statistically significant heterogeneity in the models for tumor grade (*P*\<0.001, *I*^2^=86%).

Survival outcomes
-----------------

Most of the 10 studies showed a trend toward better overall survival in patients who underwent primary tumor resection compared with those who did not receive surgery, expressed as the MOS and/or 5-year overall survival rate ([Table 4](#t4-ott-11-975){ref-type="table"}). Additionally, the MOS was 36--137 and 13.2--65 months in the surgical and nonsurgical groups, respectively, and the 5-year overall survival rate was 35.7--83 and 5.4%--50%, respectively, in these two groups. The single exception was the study by Bettini et al,[@b19-ott-11-975] who reported no difference in survival between the groups (5-year overall survival: 40% in the surgical group vs 42% in the nonsurgical group; *P*=0.74), although the median survival was longer in the surgical group (54.3 vs 39.5 months). All studies included in the meta-analysis were combined using a fixed effects model, which demonstrated that survival was significantly improved in patients who underwent primary tumor resection (*P*\<0.001), with a pooled HR of 0.36 (95% CI: 0.30--0.45) ([Figure 4](#f4-ott-11-975){ref-type="fig"}). No significant heterogeneity was detected across the studies (*I*^2^=0%, *P*=0.83). Publication bias was examined via Egger's regression test ([Figure 5](#f5-ott-11-975){ref-type="fig"}), which indicated that there was no significant publication bias (*P*\>0.05) in the outcomes of this meta-analysis.

Discussion
==========

The aim of the present study was to evaluate, through a systematic literature review, the potential benefits of primary tumor resection in patients with PNETs and unresectable liver metastases compared to other treatments that did not include surgery. Although there were no RCTs, 10 retrospective studies were included. Nine studies demonstrated that surgery yielded a significant improvement in survival, but only one study reported a nonsignificant tendency toward improved survival ([Table 4](#t4-ott-11-975){ref-type="table"}). Furthermore, all of the studies included in the meta-analysis showed that patients who underwent primary tumor resection had better overall survival compared with patients who did not undergo resection (*P*\<0.001), with a pooled HR of 0.36 (95% CI: 0.30--0.45) ([Figure 4](#f4-ott-11-975){ref-type="fig"}).

Given the relatively low incidence, the heterogeneity, and different clinical presentation of PNETs, it is difficult to develop standardized treatment strategies and start multicentre randomized trials, particularly in patients with PNETs and unresectable liver metastases. Recent guidelines from the European Neuroendocrine Tumor Society, North American Neuroendocrine Tumor Society, and National Comprehensive Cancer Network suggest that the resection of the primary tumor and the hepatic metastases should be performed when radical resection is achievable.[@b25-ott-11-975]--[@b28-ott-11-975] Unfortunately, this is possible only in \~10% of patients with metastatic PNETs. For the vast majority of these patients, the impact of palliative resection on the primary tumor is still debated. Regarding primary resection, international guidelines distinguish tumors that arise from the small intestine from those that arise from the pancreas. Resection of the primary tumor is strongly recommended for intestinal NETs, even in the presence of liver or lymph node metastasis,[@b29-ott-11-975],[@b30-ott-11-975] but resection of the primary tumor in patients with metastatic PNETs is not recommended, except for selected low-risk patients with life-threatening symptoms due to complications of the primary lesion.[@b31-ott-11-975]

Recently, three retrospective population-based observational studies used the surveillance, epidemiology, and end results database to identify patients with metastatic PNETs who underwent palliative resection of the primary tumor. Franko et al[@b23-ott-11-975] included patients who were treated between 1973 and 2003, while the study by Hüttner et al[@b24-ott-11-975] included patients who were treated from 2004 to 2011. To prevent the duplication of data, the study by Keutgen et al,[@b32-ott-11-975] who included patients across both time periods, was excluded from the present analysis. Keutgen et al found that the median survival of patients who underwent resection of the primary site was 65 months (95% CI: 60--86) vs 10 months (95% CI: 8--12) for patients who did not undergo resection (*P*\<0.001), and all three studies reported highly consistent multivariate HRs that demonstrated prolonged overall survival in the surgical group.

In the present study, overall survival appeared to be longer in patients who underwent a resection of the primary tumor. However, no RCTs evaluated the outcomes of palliative primary PNET resection in patients with stage IV disease. The majority of included studies were retrospective cohort series, which might have therefore been subject to publication bias, although Egger's regression test indicated that there was no significant publication bias (*P*\>0.05) in the outcomes of this meta-analysis ([Figure 5](#f5-ott-11-975){ref-type="fig"}). A bias toward a more aggressive surgical approach in patients with better performance status, less advanced disease, or a tumor located in the body or tail of the pancreas appears likely. Keutgen et al[@b32-ott-11-975] demonstrated that patients in the surgery group were significantly younger (\<65 years) and had more grade I tumors and more tumors located in the body/tail of the pancreas compared with patients who did not undergo surgery. Patients with body or tail tumors had a longer overall survival (HR =1.71, 95% CI: 1.43--2.04, *P*\<0.001), although this was not significantly different in the multivariate analysis. Additionally, Franko et al[@b23-ott-11-975] found that the likelihood of resection of the primary tumor was highly dependent on tumor grade: 79% of grade I and II primary tumors were resected compared to 25% of grade III and IV tumors (*P*\<0.001), which was also observed in our study.

Another confounding factor is the different types of patients included in the studies. First, some studies included patients other than patients with PNETs, with some of the patients having ileum, lung, stomach, rectum, and unknown primary NETs.[@b17-ott-11-975],[@b22-ott-11-975] Patients with midgut NETs were the main group of people together with patients with PNETs in the studies, and more and more evidence confirmed a survival benefit for primary tumor resection among midgut NET patients. Second, the inclusion of patients with liver metastasis and other distant metastasis or metastasis of sites other than the liver, such as bone metastasis, retroperitoneum metastasis, and distant lymph node metastasis,[@b9-ott-11-975],[@b23-ott-11-975] is another variable to address. Since the liver is the most common site of distant metastasis in patients with PNETs, it was not surprising to find little data available concerning primary tumor resection in the presence of other distant metastases. Bertani et al reported that the presence of extrahepatic disease was not associated with a worse survival in a univariate analysis (*P*=0.25), but the numbers were small, and the statistical power was limited. Furthermore, the multivariate analysis revealed a survival advantage for patients who underwent primary tumor resection, after excluding these patients with extrahepatic metastases from the analysis. Third, four studies included patients without liver metastases at the time of surgery.[@b9-ott-11-975],[@b21-ott-11-975],[@b23-ott-11-975],[@b24-ott-11-975] Finally, data from patients who underwent resection of the primary tumor alone were often not separated from data related to patients who also underwent liver resection.[@b17-ott-11-975],[@b21-ott-11-975],[@b22-ott-11-975] Therefore, the clinical relevance of the survival advantage reported for patients who underwent resection of the primary tumor should be considered with caution.

The present meta-analysis did not attempt to evaluate symptom response or quality of life implications following surgery, due to the insufficient number of studies that reported these outcomes. In addition, the role of nonsurgical medical therapies and the value of synchronous or delayed surgical debulking of liver metastases were not evaluated.

Compared with midgut NETs, PNETs have a worse prognosis and more operation complications. Surgical morbidity and mortality following PNET resection were not reported consistently.[@b23-ott-11-975],[@b24-ott-11-975],[@b32-ott-11-975] In our study, the postoperative mortality was 0, while the rate of postoperative abdominal complications, including pancreatic fistula, abdominal fluid collections, and bleeding, ranged from 15.9 to 42.1% ([Table 2](#t2-ott-11-975){ref-type="table"}). Compared to the operative mortality, which ranged from 0 to 3.5% in other studies, the operative mortality was lower in our study. This finding supported the safety of primary tumor resection in patients with PNETs.

Conclusion
==========

Our review highlights the possible benefits of an aggressive surgical approach in patients with metastatic PNETs, although a bias toward a more aggressive surgical approach in patients with better performance status, less advanced disease, or a tumor located in the body or tail of the pancreas appears likely. Nevertheless, in the absence of other data, resection of the primary tumor in patients who have PNETs and unresectable liver metastases should be considered in high-volume referral centers, with strict selection criteria and in a multidisciplinary setting of patient care, apart from resections needed to resolve life-threatening complications.
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###### 

Basic study characteristics

  Authors                           Year of publication   Country   Study duration   Study design   Study size   Median follow-up (months)                             Median age (years)                               Male%   Treatment comparison     Primary outcome
  --------------------------------- --------------------- --------- ---------------- -------------- ------------ ----------------------------------------------------- ------------------------------------------------ ------- ------------------------ ---------------------------
  Bertani et al[@b16-ott-11-975]    2014                  Italy     1998--2008       SC RCS         43           60                                                    NR                                               47      Resected vs unresected   OS (5-year survival)
  Citterio et al[@b17-ott-11-975]   2017                  Italy     1979--2005       SC RCS         139          127                                                   56                                               48      Resected vs unresected   OS (MOS, 5-year survival)
  Bertani et al[@b18-ott-11-975]    2016                  Italy     1996--2013       SC RCS         94           51                                                    NR                                               50      Resected vs unresected   OS (MOS), PFS
  Solorzano et al[@b9-ott-11-975]   2001                  USA       1988--1999       SC RCS         163          31                                                    52                                               66.9    Resected vs unresected   OS (MOS, 5-year survival)
  Bettini et al[@b19-ott-11-975]    2009                  Italy     1990--2004       SC RCS         51           26                                                    55                                               47      Resected vs unresected   OS (MOS, 5-year survival)
  Bertani et al[@b20-ott-11-975]    2017                  Italy     1994--2013       SC PCS         124          96                                                    54.5[a](#tfn1-ott-11-975){ref-type="table-fn"}   53.2    Resected vs unresected   OS (MOS)
  Nguyen et al[@b21-ott-11-975]     2007                  USA       1989--1999       SC RCS         73           41                                                    53                                               51      Resected vs unresected   OS (5-year survival)
  Du et al[@b22-ott-11-975]         2015                  China     1991--2013       SC RCS         130          NR                                                    49                                               53      Resected vs unresected   OS (5-year survival)
  Franko et al[@b23-ott-11-975]     2010                  USA       1973--2004       RPBOS          2,158        NR                                                    60                                               55.9    Resected vs unresected   OS (MOS)
  Hüttner et al[@b24-ott-11-975]    2015                  Germany   2004--2011       RPBOS          442          32.5/17.6[b](#tfn2-ott-11-975){ref-type="table-fn"}   NR                                               50.9    Resected vs unresected   OS (5-year survival)

**Notes:**

Mean age.

Mean follow-up reported as resected/unresected.

**Abbreviations:** MOS, median overall survival; NR, not reported; OS, overall survival; PFS, progression-free survival; RPBOS, retrospective population-based observational study using a national database; SC RCS, single-center retrospective cohort study; SC PCS, single-center prospective cohort study.

###### 

Patient information related to surgery

  Authors                           Patients with PNETs/total   Patients with liver metastasis/total                Functioning tumor   Number of patients                              Postoperative complications                     Postoperative mortality   
  --------------------------------- --------------------------- --------------------------------------------------- ------------------- ----------------------------------------------- ----------------------------------------------- ------------------------- ----
  Bertani et al[@b16-ott-11-975]    43/43                       43/43                                               11 (26%)            12                                              31                                              3 (25%)                   0
  Citterio et al[@b17-ott-11-975]   36/139                      139/139                                             139 (100%)          93                                              46                                              NR                        NR
  Bertani et al[@b18-ott-11-975]    94/94                       94/94                                               27 (28.7%)          31                                              63                                              NR                        NR
  Solorzano et al[@b9-ott-11-975]   163/163                     101/163[a](#tfn4-ott-11-975){ref-type="table-fn"}   0                   82                                              81                                              NR                        NR
  Bettini et al[@b19-ott-11-975]    51/51                       51/51                                               0                   19                                              32                                              8 (42.1%)                 0
  Bertani et al[@b20-ott-11-975]    124/124                     124/124                                             95 (76.6%)          63                                              61                                              10 (15.9%)                0
  Nguyen et al[@b21-ott-11-975]     73/73                       54/73                                               22 (30%)            42                                              31                                              12 (27%)                  0
  Du et al[@b22-ott-11-975]         85/130                      130/130                                             30 (23.1%)          74                                              56                                              NR                        NR
  Franko et al[@b23-ott-11-975]     2,158/2,158                 NR                                                  0                   735[b](#tfn5-ott-11-975){ref-type="table-fn"}   855[b](#tfn5-ott-11-975){ref-type="table-fn"}   NR                        NR
  Hüttner et al[@b24-ott-11-975]    442/442                     NR                                                  NR                  75                                              367                                             NR                        NR

**Notes:**

One patient without available follow-up information among 101 patients.

Included only patients with available detailed information.

**Abbreviations:** NR, not reported; PNETs, pancreatic neuroendocrine tumors.

###### 

Liver tumor burden and tumor grade in the resected and unresected groups

  Authors                           Number of patients with different liver tumor burdens   Number of patients with different tumor grades                                                                                                                       
  --------------------------------- ------------------------------------------------------- ---------------------------------------------------- ------- --------------------------------------------------- --------------------------------------------------- ---------
  Bertani et al[@b16-ott-11-975]    4/3/5[a](#tfn7-ott-11-975){ref-type="table-fn"}         11/14/6[a](#tfn7-ott-11-975){ref-type="table-fn"}    0.36    10/1/1[b](#tfn8-ott-11-975){ref-type="table-fn"}    14/8/4[b](#tfn8-ott-11-975){ref-type="table-fn"}    0.15
  Citterio et al[@b17-ott-11-975]   NR                                                      NR                                                   NR      NR                                                  NR                                                  NR
  Bertani et al[@b18-ott-11-975]    16/11/4[a](#tfn7-ott-11-975){ref-type="table-fn"}       27/24/12[a](#tfn7-ott-11-975){ref-type="table-fn"}   0.655   NR                                                  NR                                                  NR
  Solorzano et al[@b9-ott-11-975]   NR                                                      NR                                                   NR      NR                                                  NR                                                  NR
  Bettini et al[@b19-ott-11-975]    5/13/1[a](#tfn7-ott-11-975){ref-type="table-fn"}        4/21/7[a](#tfn7-ott-11-975){ref-type="table-fn"}     0.183   NR                                                  NR                                                  NR
  Bertani et al[@b20-ott-11-975]    30/33[c](#tfn9-ott-11-975){ref-type="table-fn"}         17/44[c](#tfn9-ott-11-975){ref-type="table-fn"}      0.012   4/37/2[b](#tfn8-ott-11-975){ref-type="table-fn"}    2/32/3[b](#tfn8-ott-11-975){ref-type="table-fn"}    0.045
  Nguyen et al[@b21-ott-11-975]     NR                                                      NR                                                   NR      NR                                                  NR                                                  NR
  Du et al[@b22-ott-11-975]         NR                                                      NR                                                   NR      9/17/7[b](#tfn8-ott-11-975){ref-type="table-fn"}    7/12/9[b](#tfn8-ott-11-975){ref-type="table-fn"}    0.619
  Franko et al[@b23-ott-11-975]     NR                                                      NR                                                   NR      298/59[d](#tfn10-ott-11-975){ref-type="table-fn"}   79/178[d](#tfn10-ott-11-975){ref-type="table-fn"}   \<0.001
  Hüttner et al[@b24-ott-11-975]    NR                                                      NR                                                   NR      37/16[d](#tfn10-ott-11-975){ref-type="table-fn"}    69/59[d](#tfn10-ott-11-975){ref-type="table-fn"}    0.048

**Notes:**

Number of patients with different liver tumor burdens reported as \<25/25%--50/\>50%.

Number of patients with different tumor grades reported as G1/G2/G3.

Number of patients with different liver tumor burdens reported as ≤25/\>25%.

Number of patients with different tumor grades reported as G1\<2/G3\<4.

**Abbreviation:** NR, not reported.

###### 

Overall survival data

  Authors                           MOS (months)   5-year survival rate   Statistically significant           
  --------------------------------- -------------- ---------------------- --------------------------- ------- -----------------------------
  Bertani et al[@b16-ott-11-975]    NR             NR                     82%                         50%     Yes (multivariate analysis)
  Citterio et al[@b17-ott-11-975]   137            32                     83.0%                       40.0%   Yes (multivariate analysis)
  Bertani et al[@b18-ott-11-975]    112            65                     NR                          NR      Yes (univariate analysis)
  Solorzano et al[@b9-ott-11-975]   36             21.6                   49%                         16%     Yes (multivariate analysis)
  Bettini et al[@b19-ott-11-975]    54.3           39.5                   40%                         42%     No (univariate analysis)
  Bertani et al[@b20-ott-11-975]    111            52                     NR                          NR      Yes (multivariate analysis)
  Nguyen et al[@b21-ott-11-975]     NR             NR                     60%                         30%     Yes (univariate analysis)
  Du et al[@b22-ott-11-975]         NR             NR                     33.3%                       5.40%   Yes (multivariate analysis)
  Franko et al[@b23-ott-11-975]     100.8          13.2                   NR                          NR      Yes (multivariate analysis)
  Hüttner et al[@b24-ott-11-975]    NR             NR                     47.6%                       21.0%   Yes (multivariate analysis)

**Abbreviations:** MOS, median overall survival; NR, not reported.
